Abstract: Fibrogenesis represents the universal response of the liver to chronic liver injury. Complement factor C5 has been linked to fibrosis in murine toxic liver injury and human chronic hepatitis C. C5 may also play a central role in chronic cholestatic disorders, since the BA receptor FXR has been characterized as an activator of the C3 gene. We aimed to investigate, whether C5 deficiency is able to prevent biliary fibrosis in the mouse bile-duct-ligation model. BDL for 1-4weeks was performed in either Hc(0)/Hc(0) mice (deficient for C5) or WT controls. BA levels were measured by RIA. Histological examination included HE, sirius-red and immunohistochemistry. mRNA expression was quantified by RT-PCR. Protein expression levels were determined by Western blotting or ELISA. Enzymatic MMP-activity was analysed by zymography. One week BDL leads to fibrosis in WT (F2.0±0), while it is almost absent in Hc(0)/Hc(0) mice (F0.5±0.5). No differences in fibrosis can be detected at week-4. Together with delayed fibrogenesis at week-1, fibrotic markers are decreased in Hc(0)/Hc(0) mice. Expression of the inflammatory cytokine TNF-is decreased in Hc(0)/Hc(0) mice. In parallel C5 deficiency leads to an attenuated peribiliary infiltration of CD45(+) cells in fibrotic areas together with decreased MMP-9 expression and gelatinase activity. The present study proves a functional role of C5 during biliary fibrogenesis. C5 deficiency leads to attenuated inflammation and normalized MMP-9 activity concomitantly with a significant reduction of fibrosis. C5 appears to be an attractive target for future therapeutic intervention in chronic cholestatic liver disease. The present study proves a functional role of C5 during biliary fibrogenesis. C5 deficiency leads to attenuated inflammation and normalized MMP-9 activity concomitantly with a significant reduction of fibrosis. C5 appears to be an attractive target for future therapeutic intervention in chronic cholestatic liver disease.
BA receptor FXR has been characterized as an activator of the C3 gene. We aimed to investigate, whether C5 deficiency is able to prevent biliary fibrosis in the mouse bile-ductligation model. The present study proves a functional role of C5 during biliary fibrogenesis. C5 deficiency leads to attenuated inflammation and normalized MMP-9 activity concomitantly with a significant reduction of fibrosis. C5 appears to be an attractive target for future therapeutic intervention in chronic cholestatic liver disease.
Introduction
Cholestatic liver diseases account for a substantial subset of chronic liver disease in people and are among the leading indications for liver transplantation in all age-groups [1] . In adults, PBC, PSC and cholestatic forms of hepatitis frequently progress to cirrhosis and endstage-liver disease [2, 3] . Without treatment, most patients eventually develop fibrosis and cirrhosis of the liver and may need liver transplantation in the late stage of disease [4] .
Although of different etiology, the consequence of impaired bile flow in all cholestatic disorders is the retention of bile constituents including BAs. Although, recent advances have been made in the pathophysiological understanding of liver fibrogenesis [5] , the development of effective therapies for chronic cholestatic disorders is still impaired by our insufficient knowledge of the molecular mechanisms by which cholestasis and retention of BAs injures the liver, and which fibrotic mechanism is involved. In chronic cholestatic disorders, T-lymphocytes and cytokines mediate persistent bile duct damage and biliary cells secrete fibrogenic mediators activating extracellular matrix formation by neighboring portal myofibroblasts [6, 7] . In consequence, perisinusoidal hepatic stellate cells become activated and periportal fibrotic bands develop finally leading to end-stage cirrhosis. Irrespective of the well established cytoprotective and choleretic effects of the hydrophilic BA ursodeoxycholic acid (UDCA) no clear-cut benefit has been achieved with regard to disease progression and transplant-free survival in patients with PBC and PSC [8, 9] . Recently, the side chain modified BA norUDCA has been shown to markedly improve biochemical and histological features in a mouse model of sclerosing cholangitis but clinical trials in humans are not available yet [10, 11] . In the absence of an effective medical therapy, the delineation of further targets for intervention in cholestatic liver disease is urgently needed and represents the molecular basis for future treatment strategies.
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It has been widely recognized that the complement system plays a critical role in the pathogenesis of a variety of chronic human disorders including chronic liver disease [12] .
Activation of the complement system initiates a cascade resulting in the cleavage of the central molecule of the complement system, C3, which in turn leads to a downstream cleavage of C5. The resulting products C3a, C5a and other complement components are activators of distinct cell surface receptors translating risk signals into defined cellular responses [13] .
More than two decades ago, it has been noticed that serum complement levels, particularly C3, are increased in patients with obstructive jaundice [14] , PBC [15] and PSC [16] . More recent evidence suggests, that the increase of C3 in PBC patients is not due to the underlying disease entity but rather due to cholestasis in general [17] . Similar conclusions can be drawn from the description of a PSC patient with complete obstruction of the common bile duct whose serum complement C3 and C4 levels normalized upon surgical reconstitution of bile flow [18] . Intriguingly, long-term plasma exchange treatment of patients with PBC even improved liver function and decreased fibrosis marker procollagen III aminopeptide along with reduced C3 activation [19] .
These clinical observations highlight the possibility of a functional link between cholestasis or BA retention and complement activation on one side, and cholestasis-induced complement activation and fibrosis progression on the other side. Indeed, regulation of complement C3 expression by the nuclear BA receptor FXR has recently been demonstrated for both human and rodent genes [20] . Given the role of the complement system in chronic toxic liver injury in mice or chronic viral hepatitis C infection in humans [21, 22] , and the fact that different forms of liver injury activate fibrogenesis in a disease-specific fashion [23] , we aimed to investigate the particular role of BA-induced complement activation in biliary
fibrosis. Aim of this study was therefore to characterize the effects of C5-deficiency on fibrogenesis in the murine BDL model which exhibits similar structural alterations to those observed in chronic biliary obstruction in man.
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2. Material and methods
Animals
8-week old C5-deficient (Hc 0 /Hc 0 ) male mice (B10.D2-Hc0H2dH2-T18c/oSnJ) and age-and gender matched control animals (B10.D2-Hc1H2dH2-T18c/oSnJ) were purchased from Jackson Laboratory (Bar Harbor, Maine, USA) and kept under standard conditions. BDL or sham-laparatomy was performed in either C5-deficient mice (n=4, each group) or WT controls (n=5, each group) as described previously [24] . After 1 and 4 weeks the mice were sacrificed and liver tissue and blood samples were harvested. Paraffin-embedded sections from both time points were analyzed after HE and sirius-red staining for the degree of hepatic fibrosis. The staging was described previously [21] . Additionally liver fibrosis was assessed in all animals histologically by quantification of the sirius-red-positive area, using the Adobe Photoshop CS3 software. The animals received humane care and the study protocols were approved by the local Government's Animal Care Committee (Nr. 2008162).
mRNA isolation and real-time RT-PCR
Total RNA was isolated from liver by using Mm00445326_m1, TNF-α: Mm99999068_m1, β-actin: 4352341E.
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Western Blotting
Similar amounts of serum proteins were separated by SDS-PAGE, transferred to PVDF membrane and probed with C3 antibody (Santa Cruz, sc-20137, USA). After incubation with species-specific HRP-conjugated secondary antibody (Dianova, Hamburg, Germany) immune complexes were detected using ECL-PLUS detection kit (GE-Healthcare, Freiburg, Germany).
Densitometric quantification of Western blots was performed using Adobe Photoshop CS3.
MMP-9 Elisa
Tissue lysates were normalized for protein concentration and equal amounts were used for ELISA. Hepatic MMP-9 protein expression was quantified by ELISA according to the manufacturer's instructions (R&D Systems, DY909).
BA quantification
Serum BAs were measured using BA RIA Kit (MP Biomedicals, Ilkirch, France) according to the manufacturer's specifications.
Gelatinase assay.
Proteolytic activity of the recombinant MMP-9 mutants was shown by gelatin zymography as described before [25] . For gelatin zymography 1mg/mL gelatin was copolymerized in a 7.5% PAGE gel and 20µg protein of pooled liver lysates of each group was loaded.
In situ zymography
An unfixed liver tissue cryoslice of 3µm thickness was stained with 1µM DAPI-solution for 3min and subsequently washed in MMP-buffer. The fluorescein conjugated DQ gelatin (Molecular Probes) was dissolved at 99°C in MMP-buffer containing 1% agarose. Using an applicator, a cover slip was coated on one side with the hot agarose buffer. After 30s cooling at room temperature the cover slip is mounted onto the tissue slice and surplus buffer was rolled out to one side. The object slides were incubated overnight at 37°C in a water 9 9 saturated atmosphere. MMP-buffer: 50mM TRIS pH7.4, 100mM NaCl, 1mM CaCl 2 , 50µM ZnCl 2 .
Immunohistological analysis
Immunohistology was performed as described before [26] . Antibodies used in this study:
Primary antibodies were used at 2µg/ml and incubated on cryoslices over night at 4°C:
Collagen I (Biodesign, T40777R), CD45 (BD, 550539), MMP-9 (R&D-Systems, AF909).
Secondary antibodies: goat anti-rabbit IgG Alexa-488, goat anti-rat IgG Alexa-488, donkey
anti-goat IgG Alexa-568 (Molecular probes, A11008, A11006, A11057). 
Statistical analysis
Markers for fibrosis are elevated in WT animals, but not in C5-deficient animals
To further evaluate these differences in fibrosis progression between WT and knock out animals at the molecular level, expression of a set of relevant fibrosis-related genes was analyzed at week 1. 3C ). To finally localize this enzymatic activity, in-situ zymography determined an increased gelatinase activity around the fibrotic bile ducts in WT-BDL mice ( fig.3D ).
Infiltration of leukocytes and concomitant MMP-9 increase in WT-BDL is absent in
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Discussion
Common bile duct obstruction inevitably initiates the process of cholangiocyte proliferation and hepatic fibrogenesis ultimately leading to liver cirrhosis unless a reconstitution of bile flow can be facilitated either by surgery or drainage [27] . Evidence from a limited number of studies and individual observations, points to an activation of complement components, particularly C3, during obstructive cholestasis [14, 17, 18] . These former observations have been reproduced in a recent analysis of the biliary transcriptome in a mouse model of experimental biliary atresia where the overexpression of the C3a receptor and C1 is suggestive of the activation of the complement cascade during bile duct injury and obstruction [28] . An increased complement C3 protein level could be observed in our study in both, Hc 0 /Hc 0 -BDL and WT-BDL mice, which can be explained by the fact that C3 is located upstream to C5 in the complement activation cascade. This finding is well in accordance with the observed increase in serum BA levels. It has recently been shown that complement C3 expression is inducible by BAs and their nuclear receptor FXR [20] . Furthermore, BA overload causes adaptive changes in hepatocellular transporter expression as observed by decreased basolateral Ntcp [24] and the induction of the retrograde basolateral salvage transporters Mrp3 and 4 [29] which can observed in our study.
Experimental common BDL induces dynamic changes in mouse livers. In parallel to bile duct proliferation which is detectable starting from day 3 and continuously increasing until day 14 after BDL, liver fibrosis visualized by sirius-red staining is increasing from day 5 until day 14 without further deterioration thereafter [30] . In our study, bile duct-ligated wildtype mice develop fibrosis stage F2 at day 7 which is completely absent in 3 out of 4 C5-deficient mice (F0). This finding was confirmed by a reduced sirius-red-positive area in histology in Hc 0 /Hc 0 -animals is of transient nature, since histology after 4 weeks of BDL revealed similar fibrosis stages in both C5-deficient and WT animals. The significant delay of biliary fibrosis after 1 week of BDL in C5-deficient mice was paralleled by reduced mRNA levels of fibrosisassociated genes including collagen I and collagen III, the stellate cell activation marker α-SMA, the profibrotic cytokine TGF-β, as well as β6-integrin, as part of the αvβ6-integrin [31].
Together with an increased mRNA expression of the proinflammatory cytokine TNF-α in WT-BDL animals, an excess of infiltrating leukocytes was monitored around the fibrotic bile ducts. Additionally, an increase of MMP-9 expression during chronic biliary obstruction has been described in WT livers [30] which could also be detected in our study. Another recent study on C5a-receptor-deficient mice demonstrated a protection against ethanol induced liver damage in a complement-and macrophage-dependent, but toll like receptor-4 independent way [33] . A reduced TNF-α expression in C5a-receptor-deficient animals in this study confirms our findings. A similar decrease in MMP-9 with antifibrotic intervention in obstructive cholestasis has been observed in the past after application of liver growth factor [34] and captopril [35] .
It becomes more and more evident that the complement system plays an important pathophysiological role in chronic liver disease irrespective of the underlying mechanism.
After the first publication of C5 as a modifier of fibrosis in chronic toxic liver injury in mice and chronic viral hepatitis C infection in humans [21] , several reports confirmed the pathophysiological impact of the complement system on viral hepatitis C [22] , non-alcoholic fatty liver disease [36] and alcoholic liver disease [37] . Genetic studies in healthy subjects have demonstrated that C5 haplotype-tagging polymorphisms as common gene variants contribute to variations in the serum activity of the profibrogenic C5 [38] . Taken together C5 appears to be an attractive target for future therapeutic intervention in chronic cholestatic liver disease. 
